BioSpace News Archive

Findings from a second interim analysis of a first-in-human Phase I/II clinical trial of Translate Bio’s CF mRNA candidate, MRT5005, show the drug did not significantly improve lung function in patients with CF.

It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.

Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.

The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.

Aktis Oncology launched today with significant financing in hand to advance a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company’s launch was supported by pharma giants including Bristol Myers Squibb and Novartis.

More than a dozen countries have suspended deployment of the AstraZeneca-Oxford University vaccine after cases of blood clots were reported.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.

According to an interview with Soumya Swaminathan, the WHO’s chief scientist, the new investigational COVID-19 vaccines rely on alternative technologies and systems of delivery. Some include oral and nasal administration, while others use skin patches.

European genetic studies aren’t particularly accurate when applied to Middle East populations, according to new research from the Qatar Foundation.